ArticleTranslational oncology2022

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.

Xin Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.